Calidi Biotherapeutics, Inc.
CLDI
$0.18
$0.00-0.11%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -18.57% | -35.91% | -36.99% | -32.99% | -19.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.05% | -28.18% | -32.43% | -33.78% | -24.89% |
| Operating Income | 7.05% | 28.18% | 32.43% | 33.78% | 24.89% |
| Income Before Tax | 9.67% | 23.40% | 13.75% | 33.14% | 23.99% |
| Income Tax Expenses | 7.14% | 150.00% | -55.00% | -18.75% | -12.50% |
| Earnings from Continuing Operations | 9.66% | 23.35% | 13.79% | 33.13% | 23.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 137.88% | 1,266.67% | -- | -- | -- |
| Net Income | 10.10% | 24.08% | 14.60% | 33.61% | 24.21% |
| EBIT | 7.05% | 28.18% | 32.43% | 33.78% | 24.89% |
| EBITDA | 8.26% | 33.89% | 37.88% | 40.02% | 31.37% |
| EPS Basic | 86.62% | 87.44% | 82.33% | 87.53% | 82.92% |
| Normalized Basic EPS | 87.96% | 88.46% | 80.65% | 88.94% | 83.96% |
| EPS Diluted | 86.62% | 87.44% | 82.33% | 87.53% | 82.92% |
| Normalized Diluted EPS | 87.96% | 88.46% | 80.65% | 88.94% | 83.96% |
| Average Basic Shares Outstanding | 543.97% | 569.79% | 510.44% | 488.86% | 374.66% |
| Average Diluted Shares Outstanding | 543.97% | 569.79% | 510.44% | 488.86% | 374.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |